Assembly Biosciences stock traded on Nasdaq, while UBS cut its price target but maintained a Buy rating, following an SEC disclosure.
2 reports, 1 independent
Updated Tue 00:00
Still developing
Reached 2 outlets in its first 24 hours
- Reports
- 2
- Developments
- 1
- Repetition
- 50%
New informationRepeats or wire copies
AI-generated analysis. Brind wrote this summary from the reports listed below. It can be wrong. Each section says how much you can rely on it, and the sources are linked so you can check.
What happened
Assembly Biosciences stock traded on Nasdaq, while UBS cut its price target but maintained a Buy rating, following an SEC disclosure.
Who's involved
What this event is mainly aboutKeep exploring
The entities involved
-
Nasdaq
American fully electronic stock exchange
-
UBS
Swiss multinational investment bank and financial services company
-
SEC
Slovak company
Related events
- FirstCash traded on the Nasdaq stock exchange, filed required reports with the SEC, and saw its stock price affected by analyst ratings.
- BioPharma stock was traded on the NASDAQ stock exchange on July 30, 2026, with its performance tracked by financial blogs.
- Crescent Capital BDC, Inc. stock traded on the Nasdaq exchange and filings were made with the SEC on May 27, 2026.
- Arrive AI traded on the Nasdaq stock exchange, with its performance covered by financial blog MarketBeat.
- UBS analyzes the tech sell-off on Nasdaq, citing Amazon's comments on AI investment.